A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective trials and retrospective analyses.

Objective

The objective of this review is to summarize the clinical outcomes of ICI-based therapies in ncc-subtypes and in tumors with sarcomatoid/rhabdoid features.

Methods

We performed a systematic literature search using PubMed, Google Scholar and ASCO databases. The keywords "renal cell cancer" and "immune checkpoint inhibitors" and equivalents were used and all original publications between July 2016 and July 2021 were included.

Re

SUBMITTER: Palma Dos Reis AF 

PROVIDER: S-EPMC9490428 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature